

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 30, 2009

Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

Docket No.: LeA36248  
82439(303989)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Heike Gielen-Haertwig

Application No.: Application No.: 10/527,391  
Assigned Patent No. 7,615,561  
To be issued: November 10, 2009

Confirmation No.: 8624

Filed: October 21, 2005

Art Unit: 1624

For: PYRIMIDINONE DERIVATIVES AS  
THERAPEUTIC AGENTS AGAINST  
ACUTE AND CHRONIC  
INFLAMMATORY, ISCHAEMIC AND  
REMODELLING PROCESS

Examiner: D. R. Rao

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Office of Petitions (Section 1.313(c)(2) petition)  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Commissioner:

Submitted concurrently herewith is a Petition to Withdraw from Issue and the requisite Request for Continued Examination in compliance with 37 C.F.R. § 1.114. Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed concurrently with the Request for Examination of the Application.

In accordance with § 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR § 1.98(a)(2).

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 82439(303989).

Dated: October 30, 2009

Respectfully submitted,

Electronic signature: /Gabriel J. McCool/  
Gabriel J. McCool

Registration No.: 58,423  
EDWARDS ANGELL PALMER & DODGE  
LLP

P.O. Box 55874  
Boston, Massachusetts 02205  
(203) 353-6875  
Attorneys/Agents For Applicant